[go: up one dir, main page]

MX2020008247A - Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. - Google Patents

Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer.

Info

Publication number
MX2020008247A
MX2020008247A MX2020008247A MX2020008247A MX2020008247A MX 2020008247 A MX2020008247 A MX 2020008247A MX 2020008247 A MX2020008247 A MX 2020008247A MX 2020008247 A MX2020008247 A MX 2020008247A MX 2020008247 A MX2020008247 A MX 2020008247A
Authority
MX
Mexico
Prior art keywords
radiohalogenated
psma
polyaminocarboxylates
urea
cancer radiotherapy
Prior art date
Application number
MX2020008247A
Other languages
English (en)
Inventor
Martin G Pomper
Ronnie C Mease
Vivek Kumar
Sangeeta Ray
Michael Zalutsky
Ganesan Vaidyanathan
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2020008247A publication Critical patent/MX2020008247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B39/00—Halogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen inhibidores de PSMA radiohalogenados de molécula pequeña y complejos metálicos de Los mismos y su uso en radio-imagenologia y radioterapia para tratar enfermedades relacionadas con PSMA, incluyendo el cáncer de próstata. También se describe la combinación de inhibidores de PSMA radiohalogenados de molécula pequeña con un ligando de PSMA competitivo para reducir la acumulación fuera de diana del inhibidor de PSMA radiohalogenado.
MX2020008247A 2018-02-06 2019-02-06 Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. MX2020008247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626993P 2018-02-06 2018-02-06
PCT/US2019/016821 WO2019157037A1 (en) 2018-02-06 2019-02-06 Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Publications (1)

Publication Number Publication Date
MX2020008247A true MX2020008247A (es) 2021-02-26

Family

ID=67549121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008247A MX2020008247A (es) 2018-02-06 2019-02-06 Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer.

Country Status (12)

Country Link
US (3) US11813340B2 (es)
EP (1) EP3749653A4 (es)
JP (1) JP7503495B2 (es)
KR (1) KR20200141439A (es)
CN (2) CN120172924A (es)
AU (1) AU2019217838C1 (es)
BR (1) BR112020016040A2 (es)
CA (1) CA3090495A1 (es)
EA (1) EA202091876A1 (es)
IL (1) IL276528B2 (es)
MX (1) MX2020008247A (es)
WO (1) WO2019157037A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220273826A1 (en) * 2019-07-02 2022-09-01 Novartis Ag Prostate specific membrane antigen (psma) ligands and uses thereof
WO2021001360A1 (en) * 2019-07-02 2021-01-07 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
EP3919082A1 (en) 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
JP2023532081A (ja) * 2020-06-29 2023-07-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物
CN111909105B (zh) * 2020-07-22 2021-09-28 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其金属标记物及制法和应用
EP4247798A1 (en) * 2020-11-19 2023-09-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
WO2025029963A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [ 177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025042989A1 (en) * 2023-08-21 2025-02-27 The Johns Hopkins University Psma-based albumin binding agents for targeted radionuclide therapy of prostate cancer
KR20250062978A (ko) * 2023-10-31 2025-05-08 서울대학교병원 신규한 전립선 특이적 막 항원 리간드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472541B1 (en) 2002-01-10 2009-09-16 The Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
US20080193381A1 (en) 2006-11-08 2008-08-14 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CN104774175B (zh) 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
RU2494096C2 (ru) * 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2009322167B2 (en) * 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
ES2941937T3 (es) 2011-11-30 2023-05-26 Univ Johns Hopkins Compuesto dirigido a PSMA y sus usos
US9760886B2 (en) * 2013-05-10 2017-09-12 Visa International Service Association Device provisioning using partial personalization scripts
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3536345A1 (en) * 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US20200231614A1 (en) 2015-10-22 2020-07-23 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
HUE065327T2 (hu) 2016-03-22 2024-05-28 Univ Johns Hopkins Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
US20250177580A1 (en) 2025-06-05
IL276528A (en) 2020-09-30
IL276528B1 (en) 2024-07-01
AU2019217838C1 (en) 2024-05-02
AU2019217838B2 (en) 2024-02-01
JP7503495B2 (ja) 2024-06-20
US11813340B2 (en) 2023-11-14
EA202091876A1 (ru) 2020-12-10
AU2019217838A1 (en) 2020-09-24
CN112020497A (zh) 2020-12-01
US20210220493A1 (en) 2021-07-22
BR112020016040A2 (pt) 2020-12-08
KR20200141439A (ko) 2020-12-18
WO2019157037A1 (en) 2019-08-15
US12233137B1 (en) 2025-02-25
US20250057996A1 (en) 2025-02-20
EP3749653A4 (en) 2021-12-15
CN120172924A (zh) 2025-06-20
JP2021513542A (ja) 2021-05-27
EP3749653A1 (en) 2020-12-16
CA3090495A1 (en) 2019-08-15
IL276528B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
MX2020008247A (es) Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer.
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
MX2024013525A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
MX2021002804A (es) Terapias de combinacion.
MX2024002838A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
PH12019500957A1 (en) Selective inhibitor of exon 20 insertion mutant egfr
PH12019502586B1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2019013333A (es) Inhibidores de histona desacetilasas (hdacs).
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2023006549A (es) Inhibidores de alc1 y sinergia con parpi.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
WO2019051025A3 (en) Treatment for aggressive cancers by targeting c9orf72
ZA202109658B (en) Chromosome conformation markers of prostate cancer and lymphoma
IL311668A (en) A CYP11A1 inhibitor for use in the treatment of prostate cancer
PL4175639T3 (pl) Masitinib w leczeniu nowotworu gruczołu krokowego opornego na kastrację
MX2023015288A (es) Terapia combinada con inhibidores de erk1/2 y egfr.
EA202190600A1 (ru) Комбинированная терапия для лечения рака предстательной железы